Study suggests Vero cells could expand FIP coronavirus research: full analysis

CURRENT FULL VERSION: A new Veterinary Record Open study suggests feline infectious peritonitis research may have gained a more practical lab tool: investigators successfully propagated feline coronavirus from three clinically diagnosed FIP cases in Vero cells and observed the kind of cytopathic changes virologists look for when a virus is adapting and replicating in culture. Published on February 25, 2026, the work frames Vero CCL-81 cells as a possible alternative platform for isolating naturally circulating FCoV strains tied to FIP. (pmc.ncbi.nlm.nih.gov)

That matters because FCoV has long been a frustrating virus to study in vitro. Prior work has noted that feline coronavirus research, particularly for serotype I viruses, has been constrained by the lack of susceptible cell lines, with much of the field relying on a limited set of feline-derived systems or specialized intestinal epithelial cultures. In the new study, the authors explicitly set out to test whether a more widely available non-feline line could support propagation of wild-type virus from clinical cases. (veterinaryresearch.biomedcentral.com)

The case series was small but clinically grounded. The team investigated three male cats with effusive FIP that presented to The Animal Hospital at Murdoch University. The cats, aged 6 to 12 months, were identified between July and September 2024 and came from the same region of Perth, Western Australia. Across the cases, the authors reported lymphopenia in all cats, along with abnormalities including leukopenia, neutropenia, regenerative left shift, hyperbilirubinemia, hypoalbuminemia, bilirubinuria, and proteinuria. After RT-qPCR confirmation, peritoneal effusion samples were inoculated into Vero cells and monitored over serial passages. (pmc.ncbi.nlm.nih.gov)

In culture, mild cell rounding appeared by day 5 post-infection in the first passage, then intensified through days 6 and 7. In the second passage, characteristic cytopathic effect appeared as early as day 2, with cell rounding, shrinkage, detachment, monolayer clearing, and cell death. The authors say declining Ct values across passages supported active replication rather than simple carryover of viral nucleic acid. They also note that the growth pattern is suggestive of FCoV-2, though they did not perform the serologic work needed to confirm genotype, and they acknowledge that multiplex PCR or metagenomics will be needed in future studies to better exclude co-infections. (pmc.ncbi.nlm.nih.gov)

The broader FIP research environment helps explain why this paper may draw attention despite its limited sample size. Updated ABCD guidance says horizontal transmission of FIP-associated strains is generally considered very unlikely, but it also flags the unusual 2023 Cyprus outbreak involving the proposed FCoV-23 strain as a rare exception under investigation. ISFM guidance adds more practical context: the Cyprus outbreak has affected increasing numbers of cats since January 2023, spread rapidly including to indoor cats, and raised concern that a highly virulent strain may cause FIP more readily than typical feline coronaviruses, potentially without requiring the usual within-host mutation step. That has led to advice on hygiene, limiting cat movement from Cyprus without testing, and reducing group housing and fecal exposure, especially in rescue and rehoming settings. The same guidance notes that legal antiviral options including remdesivir and GS-441524 are now available in Cyprus, although cost may limit access. (abcdcatsvets.org)

Meanwhile, UC Davis researchers reported in January 2026 that FIP infects a broader range of immune cells than previously thought, not just the cell populations classically emphasized. In lymph node samples from cats with naturally occurring FIP, they identified viral material in B lymphocytes and T lymphocytes as well as other immune cells, with evidence that the virus was actively replicating rather than merely leaving residual fragments. The group also reported that viral traces could persist in immune cells after antiviral treatment and apparent clinical recovery, a finding that may help explain relapse or longer-term immune dysregulation and that strengthens interest in naturally occurring FIP as a model for chronic coronavirus-associated inflammation and post-viral syndromes, including long COVID. (vetcandy.com)

No outside expert quote directly addressing this Vero-cell paper was readily available in public coverage, but the surrounding literature points to why the field is likely to care. The Murdoch group argues that Vero-based propagation could support complete genome sequencing, host-virus interaction studies, antiviral resistance work, drug screening, and early vaccine research. That fits with a period of rapid movement in FIP science, where antiviral treatment options have improved outcomes for many cats, but basic virology questions, including cell tropism, genotype-specific behavior, and mechanisms of persistence, remain unsettled. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this is a research-methods story with downstream clinical relevance. A more accessible culture system could make it easier for academic and diagnostic labs to work with contemporary field isolates, compare viral behavior across outbreaks, and test susceptibility patterns as antiviral use expands. It won’t change how veterinarians diagnose or manage FIP tomorrow, but it could help generate the lab evidence that shapes future diagnostics, therapeutics, and possibly vaccine strategies. The caveat is that Vero cells are not feline cells, and the authors themselves note that their interferon-deficient biology limits their usefulness for pathogenesis and immune-response questions. At the same time, the Cyprus outbreak and the UC Davis immune-cell findings underscore why better lab tools matter now: the field is trying to answer not just whether FCoV can be grown more easily, but how unusual strains spread, how broadly the virus targets the immune system, and whether persistence after treatment contributes to relapse or chronic inflammation. (pmc.ncbi.nlm.nih.gov)

What to watch: The next steps are straightforward: genotype confirmation, replication of the findings in larger datasets, testing in additional cell systems, and evidence that this platform can reliably support sequencing and antiviral screening using current clinical isolates, including strains implicated in unusual outbreak settings such as Cyprus. Researchers will also likely watch whether easier propagation helps connect cell-culture findings with newer in vivo questions around immune-cell tropism, viral persistence after treatment, and outbreak-associated virulence. (pmc.ncbi.nlm.nih.gov)